BioSpace News Archive

Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced that it will host a virtual key opinion leader and investor event focused on the scientific rationale and clinical development of seclidemstat, the Company’s lead drug candidate.

Gritstone bio, Inc. today announced that the Compensation Committee of the company’s Board of Directors has granted five employees nonqualified stock options.

Mustang Bio, Inc. announced that it was one of 28 recipients awarded tax incentives from the Massachusetts Life Sciences Center.

Revive Therapeutics Ltd. is pleased to announce it has entered into an agreement with the University of Health Sciences Antigua to collaborate on utilizing Revive’s novel psychedelic-assisted therapies and pioneering the clinical research and development of psychedelics in Antigua and Barbuda.

VBI Vaccines Inc. announced that two abstracts featuring data from the Phase 3 clinical program of the Company’s prophylactic 3-antigen hepatitis B vaccine candidate have been accepted for upcoming e-poster presentations at the Global Hepatitis Summit 2020/2021 and the American Diabetes Association’s Virtual 81st Scientific Sessions.

LENZ Therapeutics today emerged from stealth mode with a $47 million Series A financing from Versant Ventures and RA Capital Management.

At its 2021 Virtual Investor Day today, Bruker Corporation (Nasdaq: BRKR) will discuss the Company’s strategy and Project Accelerate 2.0 initiatives, including the Company’s potential high-growth opportunities in the areas of proteomics and spatial biology.

Diamond Therapeutics Inc. is pleased to announce the selection of BioPharma Services Inc. as the contract research organization (CRO) for its Phase 1 clinical trial.

Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer

InMed Pharmaceuticals Inc. announced that its continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach in advance of large-scale production.